Ocular Therapeutix OCUL Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $52.04M+0.2% | $51.95M-6.9% | $55.78M-1.6% | $56.66M-5.0% | $59.65M-6.4% | ||
| $6.64M+1.0% | $6.57M+5.9% | $6.21M+3.6% | $6M+7.8% | $5.56M-1.1% | ||
| $45.4M0.0% | $45.38M-8.5% | $49.57M-2.2% | $50.67M-6.3% | $54.08M-6.9% | ||
| 87.2%-0.1pp | 87.3%-1.5pp | 88.9%-0.5pp | 89.4%-1.3pp | 90.7%-0.5pp | ||
| $220.45M+11.9% | $197.1M+5.2% | $187.29M+8.9% | $171.98M+14.8% | $149.76M+17.3% | ||
| $56.35M+4.5% | $53.92M+4.1% | $51.81M+5.1% | $49.29M+8.2% | $45.56M+9.5% | ||
| $68.03M+5.7% | $64.38M+5.0% | $61.32M+6.6% | $57.53M-8.5% | $62.85M+3.6% | ||
| $351.48M+9.2% | $321.97M+5.0% | $306.62M+7.7% | $284.8M+8.0% | $263.73M+12.0% | ||
| -$299.44M-10.9% | -$270.02M-7.6% | -$250.83M-10.0% | -$228.13M-11.8% | -$204.08M-18.8% | ||
| -575.4%-55.7pp | -519.8%-70.1pp | -449.7%-47.1pp | -402.6%-60.5pp | -342.2%-72.6pp | ||
| $11.63M-1.7% | $11.83M-2.3% | $12.11M-1.8% | $12.33M-1.4% | $12.51M-7.9% | ||
| $20.58M+12.1% | $18.35M+17.0% | $15.68M-10.9% | $17.61M-12.8% | $20.19M-0.5% | ||
| $8.94M+119% | $4.08M— | —— | —— | —— | ||
| -$290.5M-9.2% | -$265.94M-6.5% | -$249.67M-15.2% | -$216.75M-12.5% | -$192.71M+0.4% | ||
| -558.2%-46.3pp | -511.9%-64.3pp | -447.6%-65.1pp | -382.5%-59.4pp | -323.1%-19.4pp | ||
| -$1.44-1.4% | -$1.42+0.7% | -$1.43-12.6% | -$1.27-11.4% | -$1.14+8.8% | ||
| -$1.44-1.4% | -$1.42+0.7% | -$1.43-12.6% | -$1.27-11.4% | -$1.14+8.8% | ||
| 767.9M+7.7% | 713.2M+4.2% | 684.2M+2.5% | 667.2M+1.0% | 660.5M+6.0% | ||
| 767.9M+7.7% | 713.2M+4.2% | 684.2M+2.5% | 667.2M+1.0% | 660.5M+6.0% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $20.58M+12.1% | $18.35M+17.0% | $15.68M-10.9% | $17.61M-12.8% | $20.19M-0.5% | ||
| $52.04M+0.2% | $51.95M-6.9% | $55.78M-1.6% | $56.66M-5.0% | $59.65M-6.4% | ||
| -$299.44M-10.9% | -$270.02M-7.6% | -$250.83M-10.0% | -$228.13M-11.8% | -$204.08M-18.8% | ||
| -$294.81M-11.0% | -$265.69M-7.7% | -$246.81M-10.1% | -$224.22M-12.0% | -$200.23M-19.2% | ||
| -$294.81M-11.0% | -$265.69M-7.7% | -$246.81M-10.1% | -$224.22M-12.0% | -$200.23M-19.2% | ||
| -566.5%-55.1pp | -511.4%-69.0pp | -442.4%-46.7pp | -395.7%-60.0pp | -335.7%-72.1pp | ||
| -$299.44M-10.9% | -$270.02M-7.6% | -$250.83M-10.0% | -$228.13M-11.8% | -$204.08M-18.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Ocular Therapeutix's profit margins?
- Gross margin is 87.2% and operating margin is -575.4%, with a -558.2% net margin.
- Where does Ocular Therapeutix's income statement data come from?
- Every line is extracted from Ocular Therapeutix's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.